Serum Macrophage Migration Inhibition Activity in Patients with Leprosy

We have found that 26 of 54 (48%) untreated patients with leprosy had serum migration inhibitory activity, and that this was present in tuberculoid, borderline, and lepromatous forms of the disease. Patients with active recreational states; i.e., reversal reactions, Lucio's reaction, or erythem...

Full description

Saved in:
Bibliographic Details
Published inJournal of investigative dermatology Vol. 79; no. 5; pp. 336 - 339
Main Authors Rea, Thomas H., Yoshida, Takeshi
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.11.1982
Subjects
AIDS/HIV
Dapsone - therapeutic use
Dinitrochlorobenzene
Humans
Hypersensitivity, Delayed
Leprosy - drug therapy
Leprosy - immunology
Macrophage Migration-Inhibitory Factors - analysis
Molecular Weight
Muramidase - blood
Prednisone - therapeutic use
Thalidomide - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:We have found that 26 of 54 (48%) untreated patients with leprosy had serum migration inhibitory activity, and that this was present in tuberculoid, borderline, and lepromatous forms of the disease. Patients with active recreational states; i.e., reversal reactions, Lucio's reaction, or erythema nodosum leprosum, were particularly apt to have this inhibitory activity. The prevalence of inhibitory activity did not vary significantly with treatment, dinitrochlorobenzene responsiveness, tuberculin responsiveness, or serum lysozyme levels.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-202X
1523-1747
DOI:10.1111/1523-1747.ep12500088